Astal Laboratories Ltd Stock Price Today (NSE: ASTALLTD)

Astal Laboratories Ltd

73.301.67 (2.23%)
Market Closed

Fundamental Score

...

Astal Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Astal Laboratories Ltd share price today is 73.30, down 2.23% on NSE/BSE as of 16 September 2026. Astal Laboratories Ltd (ASTALLTD) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 309.44 (Cr). The 52-week high for ASTALLTD share price is 103.20 and the 52-week low is 60.45. At a P/E ratio of 31.77x, ASTALLTD is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 4.39% and a debt-to-equity ratio of 0.15.

Astal Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
89.50
Low
62.80
Volume
21.3K
Change
-5.04%

Astal Laboratories Ltd share price chart: -5.04% return over the past month. 52-week high ₹103.20, 52-week low ₹60.45.

Astal Laboratories Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
74.5174.6070.5073.305.64K (Cr)
76.9079.0173.5574.9717.78K (Cr)
76.4076.4074.1076.203.26K (Cr)
77.0077.0075.3075.806.37K (Cr)
77.5077.5075.5077.3023.75K (Cr)
74.1079.0074.1078.545.34K (Cr)
76.9077.4062.8073.9928.22K (Cr)
80.3580.3574.0576.9033.03K (Cr)
79.9080.0077.9579.4439.07K (Cr)
79.7580.0077.5078.3723.00K (Cr)

Astal Laboratories Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
80.3780.6462.8073.30-8.80%
84.3589.5077.3280.60-4.45%
90.9990.9976.9584.58-7.04%
73.5091.3065.4588.96+21.03%
62.0091.9060.8673.85+19.11%
72.0077.9060.4562.13-13.71%
70.1084.0064.0565.36-6.76%
80.2084.3573.0076.60-4.49%
88.4089.0076.9979.58-9.98%
91.0092.6080.0086.85-4.56%
95.5599.9580.0090.69-5.09%
83.01103.2083.0095.74+15.34%

Returns & Performance

Poor

Return on Equity (ROE)

4.39%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

6.29%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Astal Laboratories Ltd Valuation Check

Average

Price to Earnings (P/E)

31.77x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

4.53%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

77.55%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

56.00%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.15x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

8.71x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Astal Laboratories Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ASTALLTD across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Robust Profit Growth (77.55%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (56.00%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.15)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (8.71x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Below-Average Return on Equity (4.39%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (6.29%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Low Promoter Commitment (4.53%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Astal Laboratories Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Astal Laboratories Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
30.8/100
73
₹309.44
31.8
Average
4.39%
Poor
6.29%
Poor
0.1
Excellent
0.00%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Astal Laboratories Ltd Quarterly Performance

Latest quarterly metrics for ASTALLTD — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

56.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

77.55%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Astal Laboratories Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ASTALLTD — calculated from daily price history

42RSI 14
Neutral — RSI 42

Momentum is balanced — neither overbought nor oversold.

SMA 50
82
▼ Price below SMA 50 — Short-term bearish
SMA 200
79
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
19K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Astal Laboratories Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Astal Laboratories Ltd (ASTALLTD) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Astal Laboratories Ltd

Loading latest quarterly results...

About ASTALLTD (Astal Laboratories Ltd)

Astal Laboratories Ltd is a dynamic pharmaceutical entity rooted in the vibrant city of Jaipur, India. Established in 1993 and recently rebranded in April 2024 from its previous id...entity as Macro International Limited, the company embodies a spirit of reinvention and innovation within the pharmaceutical landscape. ASTALLTD stands as a crucial player in the supply chain, focusing on the meticulous production of pharmaceutical intermediates and bulk drugs, cornerstones for the creation of finished medicinal products. Operating as a subsidiary of Aceso Research Labs LLP, the company benefits from shared expertise and resources, fostering an environment of collaborative research and development. ASTALLTD is poised to meet the growing demand for high-quality pharmaceutical components, contributing to the health and well-being of communities both locally and potentially globally. ASTALLTD's core competency lies in its dedication to manufacturing excellence. The company adheres to stringent quality control measures throughout its production processes, ensuring that its pharmaceutical intermediates and bulk drugs meet rigorous industry standards. This commitment to quality is paramount, reflecting the company's understanding of the critical role these components play in the efficacy and safety of final pharmaceutical products. By focusing on these foundational elements, ASTALLTD empowers other pharmaceutical companies to create effective and reliable medications. The facilities in Jaipur are equipped with advanced technology and staffed by skilled professionals, allowing the company to consistently deliver products that meet the exacting requirements of its diverse clientele. As Astal Laboratories Ltd embarks on this new chapter following its rebranding, it carries forward a legacy of experience combined with a renewed vision for the future. The company is strategically positioned to leverage its existing infrastructure, its skilled workforce, and the collaborative advantages of its association with Aceso Research Labs LLP. With an unwavering focus on quality, innovation, and customer satisfaction, ASTALLTD seeks to expand its presence in the pharmaceutical market, forging lasting partnerships with companies dedicated to improving global health outcomes. The Jaipur headquarters serves as a hub for research, development, and manufacturing, driving ASTALLTD's ambition to become a trusted and reliable supplier of essential pharmaceutical building blocks.

Company Details

Symbol:ASTALLTD
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Balayogiswara Rao Peddinti
Chief Financial Officer
Mr. Mahendra Kumar
Company Secretary & Compliance Officer
Mr. Sudheer Karna Kankanala
Whole Time Director

ASTALLTD Share Price: Frequently Asked Questions

What is the current share price of Astal Laboratories Ltd?

Astal Laboratories Ltd (ASTALLTD) trades at ₹73.30 on NSE and BSE. Market cap ₹309.44 (Cr). Educational data only.

What is the P/E ratio of Astal Laboratories Ltd?

Astal Laboratories Ltd has a P/E of 31.77x vs industry average 34.89x.

What is the Bull Run score for Astal Laboratories Ltd?

Astal Laboratories Ltd has a Bull Run score of 30.8/100 based on 25+ financial parameters.

Does Astal Laboratories Ltd pay dividends?

Astal Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Astal Laboratories Ltd?

Astal Laboratories Ltd has ROE of 4.39%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Astal Laboratories Ltd?

Astal Laboratories Ltd has debt-to-equity of 0.15.

Is Astal Laboratories Ltd a good investment?

Bull Run gives Astal Laboratories Ltd a score of 30.8/100. This is not investment advice — consult a SEBI-registered advisor.